TVGN vs. CRIS, ALGS, ACHL, OKYO, NKGN, CYTH, SRZN, QNCX, INKT, and ESLA
Should you be buying Tevogen Bio stock or one of its competitors? The main competitors of Tevogen Bio include Curis (CRIS), Aligos Therapeutics (ALGS), Achilles Therapeutics (ACHL), OKYO Pharma (OKYO), NKGen Biotech (NKGN), Cyclo Therapeutics (CYTH), Surrozen (SRZN), Quince Therapeutics (QNCX), MiNK Therapeutics (INKT), and Estrella Immunopharma (ESLA). These companies are all part of the "biological products, except diagnostic" industry.
Tevogen Bio (NASDAQ:TVGN) and Curis (NASDAQ:CRIS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, community ranking, valuation, institutional ownership, media sentiment, profitability and dividends.
Curis received 688 more outperform votes than Tevogen Bio when rated by MarketBeat users.
Tevogen Bio has a beta of 0.4, suggesting that its share price is 60% less volatile than the S&P 500. Comparatively, Curis has a beta of 3.44, suggesting that its share price is 244% more volatile than the S&P 500.
In the previous week, Tevogen Bio had 4 more articles in the media than Curis. MarketBeat recorded 4 mentions for Tevogen Bio and 0 mentions for Curis. Tevogen Bio's average media sentiment score of 0.00 equaled Curis'average media sentiment score.
Tevogen Bio has higher earnings, but lower revenue than Curis.
Curis has a consensus target price of $37.33, indicating a potential upside of 322.32%. Given Curis' higher possible upside, analysts clearly believe Curis is more favorable than Tevogen Bio.
Tevogen Bio has a net margin of 0.00% compared to Curis' net margin of -486.45%. Curis' return on equity of -224.75% beat Tevogen Bio's return on equity.
30.0% of Curis shares are held by institutional investors. 56.6% of Tevogen Bio shares are held by insiders. Comparatively, 5.7% of Curis shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
Curis beats Tevogen Bio on 7 of the 12 factors compared between the two stocks.
Get Tevogen Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for TVGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TVGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tevogen Bio Competitors List
Related Companies and Tools
